These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 36898827)
21. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. Shloush J; Vlassov JE; Engson I; Duan S; Saridakis V; Dhe-Paganon S; Raught B; Sheng Y; Arrowsmith CH J Biol Chem; 2011 Feb; 286(6):4796-808. PubMed ID: 21084285 [TBL] [Abstract][Full Text] [Related]
22. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. Fu W; Ma Q; Chen L; Li P; Zhang M; Ramamoorthy S; Nawaz Z; Shimojima T; Wang H; Yang Y; Shen Z; Zhang Y; Zhang X; Nicosia SV; Zhang Y; Pledger JW; Chen J; Bai W J Biol Chem; 2009 May; 284(21):13987-4000. PubMed ID: 19321440 [TBL] [Abstract][Full Text] [Related]
23. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction. Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424 [TBL] [Abstract][Full Text] [Related]
24. The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2. He Y; Tollini L; Kim TH; Itahana Y; Zhang Y Cell Cycle; 2014; 13(13):2101-9. PubMed ID: 24804778 [TBL] [Abstract][Full Text] [Related]
25. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Gupta A; Shah K; Oza MJ; Behl T Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517 [TBL] [Abstract][Full Text] [Related]
26. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370 [TBL] [Abstract][Full Text] [Related]
27. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. Wang X; Wang J; Jiang X J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037 [TBL] [Abstract][Full Text] [Related]
28. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. Okamoto K; Taya Y; Nakagama H FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542 [TBL] [Abstract][Full Text] [Related]
29. Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage. Cheng Q; Cross B; Li B; Chen L; Li Z; Chen J Mol Cell Biol; 2011 Dec; 31(24):4951-63. PubMed ID: 21986495 [TBL] [Abstract][Full Text] [Related]
30. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53. Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260 [TBL] [Abstract][Full Text] [Related]
32. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Kurokawa M; Kim J; Geradts J; Matsuura K; Liu L; Ran X; Xia W; Ribar TJ; Henao R; Dewhirst MW; Kim WJ; Lucas JE; Wang S; Spector NL; Kornbluth S Sci Signal; 2013 May; 6(274):ra32. PubMed ID: 23652204 [TBL] [Abstract][Full Text] [Related]
33. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269 [TBL] [Abstract][Full Text] [Related]
35. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Herman AG; Hayano M; Poyurovsky MV; Shimada K; Skouta R; Prives C; Stockwell BR Cancer Discov; 2011 Sep; 1(4):312-25. PubMed ID: 22586610 [TBL] [Abstract][Full Text] [Related]
36. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154 [TBL] [Abstract][Full Text] [Related]
37. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination. Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143 [TBL] [Abstract][Full Text] [Related]
38. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma. Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242 [TBL] [Abstract][Full Text] [Related]
39. MDM2 Inhibits Axin-Induced p53 Activation Independently of its E3 Ligase Activity. He Y; Lian G; Lin S; Ye Z; Li Q PLoS One; 2013; 8(6):e67529. PubMed ID: 23826318 [TBL] [Abstract][Full Text] [Related]
40. p53 regulation: teamwork between RING domains of Mdm2 and MdmX. Wang X Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]